At #WCLC2025, Iambic will present new preclinical NSCLC data on IAM1363, a potent, irreversible Type II HER2 inhibitor. IAM1363 is highly differentiated by its target selectivity, brain-penetrance, pan-mutant activity, and tumor enrichment. Learn more: iambic.ai/post/wcwc2025

Iambic CFO/CCDO Michael Secora will participate at the Citi Global TMT Conf. on Sept 5 to discuss our lead clinical program IAM1363, our leading NeuralPLexer & Enchant AI models, and new tech enablement deal with Revolution Medicines. #AI #TechBio #CitiTMTConference

Iambic CTO Fred Manby presents "Predictive Drug Discovery with Enchant v2" at Biocom California’s Converge Meet-up (Sept 10). Learn how industry-leading Enchant predicts clinical endpoints of potential drug molecules early in discovery. Event info: bit.ly/3I7UnPs

Iambic CEO Tom Miller joins UCSD’s Legends of Science Oncology Symposium for “AI in Cancer: Where Are We Going?”. He’ll show how AI has sped development of our pipeline and spotlight IAM1363, our clinical-stage type II HER2 inhibitor. Learn more: bit.ly/46kpdMU

Iambic CFO & CCDO Michael Secora is at the BofA Healthcare Trailblazers Conf. today to discuss: Upcoming IAM1363 clinical data (type II HER2 inhibitor); our new RVMD tech deal; our leading AI drug discovery models (NeuralPLexer, Enchant); and growing oncology pipeline. #Techbio

@ #ISSX2025: Iambic CEO Tom Miller joins the AI/ML symposium to share Enchant, which predicts clinical drug properties from early discovery data—speeding decisions, streamlining our pipeline & improving success odds. Learn more: issx2025.org/issx/sept23 #machinelearning #techbio

See Iambic Sr. Research Scientist David Farina on Sept. 24 at Discovery on Target as he dives into Enchant—our multimodal transformer that forecasts clinical endpoints from preclinical data and predicts biological, physicochemical, PK, metabolic & safety properties. #BostonDOT

Iambic CTO Fred Manby joins the Economist AI in Health Summit for the panel “No data, no AI” to discuss how our foundation model “Enchant” fuses scarce clinical signals with abundant preclinical data to make high-confidence predictions in low-data regimes. #EconAIHealth

We are pleased to welcome veteran biopharma finance leader Shalini Sharp to our Board of Directors and to benefit from her industry leadership and capital-markets expertise as we advance toward key clinical catalysts and corporate milestones. Learn more: iambic.ai/post/shalini-s…

Iambic CTO Fred Manby will keynote the Danish Pharmaceutical Society seminar on quantum computing + AI in pharma R&D, where he will discuss Iambic’s platform and leading drug discovery models -- and how they are driving our AI-designed clinical pipeline.

Iambic CEO Tom Miller and CFO/CCDO Michael Secora will join the Needham Private Biotech Forum on Oct. 14 to discuss anticipated IAM1363 clinical data, our pipeline, AI drug discovery models (NeuralPLexer, Enchant), and strategic platform partnerships. #TechBio #AI #DrugDiscovery

Thrilled to present new papers at NeurIPS & EurIPS and connect with fellow AI/ML innovators. We’ll share updates on our leading drug discovery models for protein structure prediction (NeuralPLexer3) and molecular property prediction (Enchant). See you in December! #DrugDiscovery

At #ESMO25, we reported Phase 1/1b data for IAM1363, our AI-designed HER2 TKI which showed antitumor activity with favorable safety/tolerability across multiple tumor types. IAM1363 went from discovery→clinic in <2 yrs; initial POC ~1 yr later. News here: iambic.ai/post/esmo-iam1…

Iambic announces research collab/drug-supply deal with Jazz Pharma. Jazz will supply zanidatamab to combine with IAM1363, our HER2 TKI, for evaluation in HER2+ breast cancer patients previously treated with T-DXd, as part of our P1/1b study of IAM1363. iambic.ai/post/jazz-iam1…

From models to medicines in three years: On October 28, Iambic CEO Tom Miller will share the story of IAM1363 at the Chen Institute Symposium on AI-Accelerated Science and discuss how our platform turns model predictions into meaningful clinical progress. aias2025.org

On Oct 30, our CEO Tom Miller joins leaders at the Galien Forum in NYC to discuss the promise & reality of AI in drug development—expectations, challenges, and the path to real-world outcomes – and to share new signals of Iambic’s continued progress. More: galienfoundation.org/galien-forum-u…

Join Iambic’s leadership this November at healthcare- and innovation-focused investor conferences as we share updates on our AI-driven discovery programs, platform advances, and early clinical progress. Learn more: iambic.ai/post/iambic-no… #AI #DrugDiscovery #TechBio

On Nov. 7 Iambic CEO & Co-founder Tom Miller keynotes the Broad Institute ML in Drug Discovery Symposium. “From Models to Medicines” shows how our AI models + automated experimentation drive patient impact and pipeline momentum. If you’ll be at the Broad, let’s connect!

Next week at the FT Global Pharma & Biotech Conference, Iambic CTO Fred Manby joins the panel “AI in pharma — from trial and error to business as usual.” He’ll discuss early clinical data showing how Iambic’s platform turned model predictions into real clinical impact. #FTPharma

Pleased to announce Iambic has raised $100M+ in an oversubscribed round to accelerate its AI-discovered therapeutics pipeline & platform. Support from new & existing life sci, tech, growth & sovereign wealth investors underscores strong conviction. More: iambic.ai/post/iambic-ra…